Publications by authors named "Filip Surmont"

Claim this Profile
C
Considerations when planning and conducting large global observational studies: Experience from the DISCOVER study of patients with type 2 diabetes.
Pernilla Aarskog, Javier Cid-Ruzafa, Hungta Chen, Peter Fenici, Larisa Ramirez Gutierrez, Filip Surmont

Prim Care Diabetes· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescribing patterns of budesonide/formoterol maintenance and reliever therapy in patients with asthma in Sweden.
Christer Janson, Erik Melén, Sofie de Fine Licht, Gunilla Telg, Ekaterina Maslova, Filip Surmont

Allergy· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
Bernard H Charbonnel, Hungta Chen, Javier Cid-Ruzafa, Andrew Cooper, Peter Fenici, Filip Surmont

Diabetes Obes Metab· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study.
Marília B Gomes, Fengming Tang, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Filip Surmont

Front Endocrinol (Lausanne)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study.
Suzanne V Arnold, Kamlesh Khunti, Fengming Tang, Hungta Chen, Javier Cid-Ruzafa, Filip Surmont

Am Heart J· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities.
Kamlesh Khunti, Hiddo J L Heerspink, Carolyn S P Lam, Antonio Nicolucci, Larisa Ramirez, Filip Surmont

J Diabetes Complications· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study.
Linong Ji, Fabrice Bonnet, Hungta Chen, Andrew Cooper, Niklas Hammar, Filip Surmont

Diabetes Res Clin Pract· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Kamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, Shun Kohsaka, Carolyn S P Lam, Filip Surmont

Cardiovasc Diabetol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies.
J Mark FitzGerald, Paul M O'Byrne, Eric D Bateman, Peter J Barnes, Jinping Zheng, Filip Surmont

Drug Saf· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 2 diabetes and heart failure: insights from the global DISCOVER study.
Suzanne V Arnold, Kamlesh Khunti, Fabrice Bonnet, Bernard Charbonnel, Hungta Chen, Filip Surmont

ESC Heart Fail· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.
Krishna K Patel, Marilia B Gomes, Bernard Charbonnel, Hungta Chen, Javier Cid-Ruzafa, Filip Surmont

Diabetes Obes Metab· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study.
Wolfgang Rathmann, Bernard Charbonnel, Marília B Gomes, Niklas Hammar, Kamlesh Khunti, Filip Surmont

Diabetes Res Clin Pract· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, Matthew A Cavender, Anna Norhammar, Filip Surmont

Lancet Diabetes Endocrinol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
Stéphane Pintat, Peter Fenici, Niklas Hammar, Linong Ji, Kamlesh Khunti, Filip Surmont

BMJ Open Diabetes Res Care· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme.
Kamlesh Khunti, Linong Ji, Jesús Medina, Filip Surmont, Mikhail Kosiborod

Diabetes Obes Metab· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Antonio Nicolucci, Bernard Charbonnel, Marília B Gomes, Kamlesh Khunti, Mikhail Kosiborod, Filip Surmont

Diabetes Obes Metab· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015.
Maryam Tabesh, Dianna J Magliano, Stephanie K Tanamas, Filip Surmont, Silver Bahendeka

Acta Diabetol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
Marilia B Gomes, Wolfgang Rathmann, Bernard Charbonnel, Kamlesh Khunti, Mikhail Kosiborod, Filip Surmont

Diabetes Res Clin Pract· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).
Mikhail Kosiborod, Marilia B Gomes, Antonio Nicolucci, Stuart Pocock, Wolfgang Rathmann, Filip Surmont

Cardiovasc Diabetol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Filip Surmont

J Am Coll Cardiol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: The LASSYC observational study.
Marc Miravitlles, Ana Menezes, Maria Victorina López Varela, Alejandro Casas, Luis Ugalde, Filip Surmont

Respir Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to inhaled therapies of COPD patients from seven Latin American countries: The LASSYC study.
Maria Montes de Oca, Ana Menezes, Fernando C Wehrmeister, Maria Victorina Lopez Varela, Alejandro Casas, Filip Surmont

PLoS One· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exacerbations and health care resource utilization in patients with airflow limitation diseases attending a primary care setting: the PUMA study.
Maria Montes de Oca, Carlos Aguirre, Maria Victorina Lopez Varela, Maria E Laucho-Contreras, Alejandro Casas, Filip Surmont

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoke, Biomass Exposure, and COPD Risk in the Primary Care Setting: The PUMA Study.
Maria Montes de Oca, Gustavo Zabert, Dolores Moreno, Maria E Laucho-Contreras, Maria Victorina Lopez Varela, Filip Surmont

Respir Care· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.
Linong Ji, Fabrice Bonnet, Bernard Charbonnel, Marilia B Gomes, Mikhail Kosiborod, Filip Surmont

J Diabetes Complications· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis